SEC Tracker
Get the app

AVROBIO TECX

AVROBIO Q1 FY24: net loss $6.8M; diluted EPS −$0.28

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers AVROBIO reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$6.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.28No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.1510-Q income statement, on EDGAR
  3. Cash and cash equivalents$90.5MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$7.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when AVROBIO files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Aldeyra Therapeutics ALDX public float $232M, Jun 30, 2025
  2. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  3. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  4. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025
  5. Annexon ANNX public float $244M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.